Willingness to pay and quality of life in patients with pruritic skin disorders
- 37 Downloads
Pruritic dermatosis is a frequent and burdensome disease. The objectives of this study were (1) to assess the willingness to pay (WTP) and the health-related quality of life (HRQoL) in patients with pruritic dermatoses and (2) to compare the results with data on socio-demographic data, and clinical features/symptoms of the patients. One hundred and three patients with pruritic dermatosis had participated in a non-interventional, cross-sectional study. Socio-demographic data, clinical features/symptoms, a health-related quality of life (HRQoL)-based and a dermatology-specific instrument (SF-6D and DLQI, respectively), and two utility indicators such as rating scale (RS) and time-trade-off (TTO) as well as willingness to pay (WTP) were recorded. In our study, there was a significant correlation between DLQI scores and WTP (p < 0.001). Time-trade-off (TTO) was also statistically correlated with SF-6D (p = 0.001). Regression models showed that daily duration and pruritus intensity were associated with lower HRQoL. Furthermore, WTP was the only measure revealing demographic and socio-economic characteristics such as age, education level, family status and income as predicting factors. No significant differences between groups of varying skin diseases were observed. HRQoL and WTP proved to be valid tools to assess the burden of disease in patients with pruritic dermatosis. However, further research with a larger number of patients is needed to validate the present findings.
KeywordsHealth-related quality of life SF-6D DLQI Time-trade-off Willingness to pay
No funding has supported this work.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Informed consent was obtained from all the participants in this study.
Ethical approval was obtained for this study.
- 2.Augustin M, Blome C, Forschner A, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Schadendorf D, Utikal J, Wagner T, Wilden S, Kähler KC (2018) Willingness to pay for a cure of low-risk melanoma patients in Germany. PLoS One 13(5):e0197780. https://doi.org/10.1371/journal.pone.0197780. (eCollection 2018)Google Scholar
- 3.Barbier N, Paul C, Luger T et al. (2004) Validation of the eczema area and severity index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol 150(1):96–102Google Scholar
- 6.Bell CM, Chapman RH, Stone PW, Sandberg EA, Neumann PJ. An off-the-shelf help list: a comprehensive catalog of preferences scores from published cost-utility analyses. Med Decis Mak 21(4):288–294Google Scholar
- 7.Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36. J Health Econ 21(2):271–292Google Scholar
- 10.Dolan P, Gudex C, Kind P, Williams A (1996) Valuing health states: a comparison of methods. J Health Econ 15(2):209–231Google Scholar
- 12.Finley AY, Khan GK (1994) A simple practical measure for routine clinical use. Clin Exp Dermatol 19(3):210–216Google Scholar
- 13.Golda N, Black W, Patel V, Neal D, Etzkorn J (2019) Determining patient preferences and willingness to pay related to scar length and appearance following skin cancer treatment on the face and trunk: A multi-center discrete choice experiment. J Am Acad Dermatol https://doi.org/10.1016/j.jaad.2019.01.080 (S0190-9622(19)30191-4)Google Scholar
- 14.Guyatt GH, Feeny DH, Patrick DL (1993) Measuring health related quality of life. Ann Intern Med 15(8):622–629 118(Google Scholar
- 19.Lundberg L, Johanneson M, Silverdahl M, Hermansson C, Lindberg M (1999) Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 141(6):1067–1075Google Scholar
- 20.Majeski CL, Johnson JA, Davison SN, Lauzon GJ (2007) Itch severity scale: a self- reported instrument for the measurement of pruritus severity. Br J Dermatol 156(4):667–673Google Scholar
- 21.McFarlane PA, Pierratos A, Bayoumi AM, Redelmeier DA (2007) Estimating preference scores in conventional and home nocturnal hemodialysis patients. Clin J Am Soc Nephrol 2(3):477–483Google Scholar
- 22.O’Brien B, Gafni A (1996) When do the “dollars” make sense? Toward a conceptual framework for contigent valuation studies in health care. Med Decis Making 16:288–299Google Scholar
- 24.Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM (1999) Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41(Pt 1):401–407 3Google Scholar
- 25.Schiffner R, Brunnberg S, Hohenleutner U, Stolz W, Landthaler M (2002) Willingness to pay and time trade-off: useful utility indicators for the assessment of quality of life and patient satisfaction in patients with port wine stains. Br J Dermatol 146(3):440–447Google Scholar
- 26.Schmitt J, Meurer M, Klon M, Frick KD (2008) Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br J Dermatol 158(2):351–359Google Scholar
- 29.Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, Yang H, Goldblum O, Okun MM, Mulani PM (2012) Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label phase IIIB trial. Br J Dermatol 167(6):1374–1381. https://doi.org/10.1111/bjd.12000 Google Scholar
- 30.Steinhoff M, Bienenstock J, Schmelz M, Maurer M, Wei E, Biro T (2006) Neurophysiological, neuroimmunological and neuroendocrine basis of pruritus. J Invest Dermatol 126(8):1705–1718Google Scholar
- 31.Torrance GW (1986) Measurements of health status utilities for economic appraisal: a review. J Health Econ 5(1):1–30Google Scholar
- 32.Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ (2002) Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 47(4):512–518Google Scholar
- 34.Yosipovitch G, Ansari N, Goon A, Chan YH, Goh CL (2002) Clinical characteristics of pruritus in chronic idiopathic urticaria. Br J Dermatol 147:32–36Google Scholar
- 35.Zhu B, Edson-Heredia E, Guo J, Maeda-Chubachi T, Shen W, Kimball AB (2014) Itching is a significant problem and a mediator between disease severity and quality of life for patients with psoriasis: results from a randomized controlled trial. Br J Dermatol 171:1215–1219Google Scholar
- 36.Zug KA, Littenberg B, Baughman RD et al (1995) Assessing the preferences of patients with psoriasis. A quantitative, utility approach. Arch Dermatol 131:561–568Google Scholar